Skip to main content

 Scientific publications

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Authors : Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA
Year : 2022
Journal : N Engl J Med
Volume : 387
Pages : 9-20

MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitie

Authors : Awada A, Gombos A
Year : 2022
Journal : TBCR
Volume : -
Pages : 4 pages

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Authors : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Year : 2022
Journal : Cancer Med
Volume : 11
Pages : 332-339

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Authors : Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, OReilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribi K, Viale G, Gelber Rd, Coates AS, Loi S, Goldhirsch A, Regan MM, Colleoni M
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1256-1266

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Authors : Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart-Gebhart M, Korde LA, Goldhirsch A, Gelber Rd, Pagani O
Year : 2021
Journal : Breast
Volume : 59
Pages : 327-338

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.

Authors : Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, Munzone E, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini E, Gombos A, Deleu I, Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson A, Graas MP, Barber M, Fontaine C, Loibl S, Gavilá J, Kuroi K, Müller B, OReilly S, Di Leo A, Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 504-512

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Authors : El Hachem G, Gombos A, Awada A
Year : 2021
Journal : Expert Rev Anticancer Ther
Volume : 21
Pages : 81-92

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.

Authors : Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ
Year : 2021
Journal : Cancer Discov
Volume : 11
Pages : 2796-2811

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.

Authors : Martel S, Lambertini M, Agbor-Tarh D, Ponde NF, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A, Maurer C, Piccart-Gebhart M, Moreno-Aspitia A, Desmedt C, Di Cosimo S, de Azambuja E
Year : 2021
Journal : J Natl Compr Canc Netw
Volume : 19
Pages : 181-189

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Authors : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Year : 2020
Journal : Clin Colorectal Cancer
Volume : 19
Pages : 311-318.e1

Selective oestrogen receptor degraders in breast cancer: a review and perspectives.

Authors : Gombos A
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 424-429

Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer.

Authors : Gombos A, Franzoi MA, Awada A
Year : 2019
Journal : Expert Opin Investig Drugs
Volume : 28
Pages : 617-627

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.

Authors : Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud W, Canon JL, Gombos A, Dalenc F, Delaloge S, Lemonnier J, Loussouarn D, Verrièle V, Campone M
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 65

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Authors : Kotecki N, Gombos A, Awada A
Year : 2019
Journal : Expert Rev Anticancer Ther
Volume : 19
Pages : 447-454

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.

Authors : El Hachem G, Gombos A, Awada A
Year : 2019
Journal : F1000Res
Volume : 8

Triple negative breast cancer: current treatment and future perspectives.

Authors : El Hachem G, Jounblat Y, Awada A, Gombos A
Year : 2019
Journal : Belgian J Medical Oncology
Volume : 13(3)
Pages : 84-92

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Authors : Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F, + collaborators (among others :, Piccart-Gebhart M
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 371-382

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Authors : Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, OReilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber Rd, Coates AS, Di Leo A, Regan MM, Goldhirsch A
Year : 2018
Journal : Lancet Oncol
Volume : 19(1)
Pages : 127-138